Our medicines aim to improve the well-being of people around the world.
Below is a list of our company's therapies. The below information is intended for U.S. residents only.
For product information for other countries, please visit your country's Biogen affiliate website.
Last Updated: January 31, 2024
*Important ADUHELM Update: Biogen has announced that it will discontinue the commercialization and development of ADUHELM® (aducanumab-avwa). Biogen will focus on LEQEMBI® (lecanemab-irmb) with Eisai and advancing potential new modalities to address the multiple pathologies of the disease and unmet patient needs. A plan for patients participating in clinical trials or on commercially available treatment is in place. Patients with questions are encouraged to call our patient support line at 1-833-425-9360.